Current Opinion in Infectious Diseases. 20(1):11–15, FEBRUARY 2007

DOI: 10.1097/QCO.0b013e328012c5f1

,  

PMID: 17197876

Issn Print: 0951-7375

Publication Date: February 2007


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

HIV and pneumococcal disease

Keith Klugman;Shabir Madhi;Charles Feldman;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose of reviewTo describe the impact of highly active antiretroviral therapy on the burden of pneumococcal disease and advances in our understanding of the impact of HIV on this disease.Recent findingsAlthough highly active antiretroviral therapy has reduced the burden of pneumococcal disease among HIV-infected adults, these infections remain far more common than in HIV uninfected adults. HIV-infected adults who smoke or have comorbidities are at particular risk. In the absence of highly active antiretroviral therapy, pneumococcal meningitis has emerged in Africa as a major disease burden with a high mortality among HIV-infected children and adults. Conjugate pneumococcal vaccine protects HIV-infected infants from pneumococcal pneumonia. In the United States, where conjugate vaccine is given to children, herd immunity has reduced the burden of invasive pneumococcal disease among HIV-infected adults.SummaryThe pneumococcus remains a significant cause of morbidity and mortality among HIV-infected children and adults, both in developed and in developing countries.

Related Topics

    Related Articles

        loading  Loading Related Articles